Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin.
BACKGROUND
Hepatocellular carcinoma (HCC) is one of the world's major malignancies, especially in Asian countries. To improve the prognosis of HCC, it is essential to predict its invasive behavior in both intra- and extra-hepatic modalities. For this purpose, we examined the predictive values of two tumor markers, alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP).


METHODS
194 HCC cases at the National Cancer Center Hospital were selected from the Pathology Records. Detailed information regarding the existence of extra-hepatic venous invasion (EHVI) at the portal vein and intra-hepatic multiple malignant tumors (IHMTs) were collected and combined with the preoperative AFP and DCP testing results. Furthermore, information about the viral infection status such as HBs antigen positive or HCV antibody positive or no viral hepatitis was obtained. The information was analyzed by the ROC (Receiver Operating Characteristic Curve) method.


RESULTS
and


CONCLUSIONS
In both the EHVI group and the IHMT group, all the combinations except the HCV-positive group of IHMT revealed a tendency for DCP to offer better diagnostic accuracies, although this was statistically significant only in the HBs-positive group of IHMT. This result indicates either (1). that in a strict sense, DCP is not necessarily better than AFP at predicting the invasive characteristics or (2). that DCP is better than AFP at reflecting the invasive characteristics of HCC although not statistically significant. In either situation, from a long-term viewpoint, it is advisable to find a new marker or to re-evaluate the existing markers in order to predict the invasive characteristics more accurately.
Gotoh
Miki
M
Department of Clinical Chemistry, National Cancer Center Hospital, Tokyo, Japan.
Nakatani
Tomohiro
T
Masuda
Taizo
T
Mizuguchi
Yasunori
Y
Sakamoto
Michiie
M
Tsuchiya
Ryosuke
R
Kato
Hoichi
H
Furuta
Koh
K
D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000737:chemistry* / Q000473:pathology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000737:chemistry* / Q000473:pathology; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011498:Protein Precursors / Q000097:blood*; D011516:Prothrombin; D012372:ROC Curve; D012680:Sensitivity and Specificity; D000509:alpha-Fetoproteins / Q000032:analysis*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D011498:Protein Precursors; D000509:alpha-Fetoproteins; C008208:acarboxyprothrombin; D011516:Prothrombin